CANCER BIOMARKER ANALYSIS IN TUMOR TISSUES

ONCOLOGY

To support drug discovery projects in oncology, we perform high-content analysis either in cellular models of human tumors in 2D or 3D, or directly in tumor tissues and blood samples. Combining a panel of validated assays for immediate performance and more than 10-year experience in assay development, we assist pharmaceutical companies and academic researchers in the discovery of new cancer drug targets, the identification of new anticancer compounds, and the quantitative analysis of novel cancer biomarkers.

CANCER BIOMARKER ANALYSIS IN TUMOR TISSUES

Fluofarma developed high-content analysis methods applicable to tumor tissues, including 3D artificial tumor microtissues, xenografts, tumor tissue sections and tumor tissues microarrays. Our high-content histopathology services are tailored for the quantitative analysis of cancer biomarkers at various stage of the drug discovery pipeline, from the in situ validation of new cancer targets up to patient stratification in clinical trials.

FLEXIBLE TUMOR TISSUE SOURCING & SAMPLING

> Exclusive access to archival human tumor tissues through a privileged partnership with a comprehensive cancer center (patient clinical data provided)

> Different tissue samples and formats can be analyzed: 3D tumor spheroids, xenografts, archival tissues or biopsies of patients in trials, either in tissue section or tissue microarray format. 

> Custom tissue microarrays can be assembled in-house to fit specific sampling strategies: multi-tumor tissue microarrays, tumor progression tissue microarrays, biopsy tissue microarrays, etc.

HIGH-CONTENT HISTOPATHOLOGY SERVICES

> Tissue microarray approach: hundreds of tumor tissue samples on a single histologic slide, to reduce turnaround time and increase experimental uniformity

> Automated tissue imaging of immunostained tissue sections or tissue microarrays (immunohistochemistry or immuno-fluorescence staining)

> Multiplexed biomarker quantification (biomarker expression level and subcellular distribution) and quantitative analysis of tumor topography using proprietary software applications.

 Representative images of p53 (A) and HIPK2 fluorescent signals (B).

The overlay and segmentation mask are respectively represented in (C) and (D).